Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GKOS Glaukos	$94.21 +4.9%	$96.26	$77.10 ▼ $163.71	$5.40B	0.78	1.21 million shs	688,079 shs
IRTC iRhythm Technologies	$169.12 +1.5%	$147.89	$55.92 ▼ $172.59	$5.43B	1.41	561,057 shs	532,031 shs
LQDA Liquidia Technologies	$26.84 -1.7%	$17.51	$8.75 ▼ $28.00	$2.31B	0.14	3.26 million shs	2.60 million shs
STVN Stevanato Group	€22.52 -1.4%	€24.34	€17.12 ▼ €28.00	€6.85B	0.55	407,842 shs	336,900 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GKOS Glaukos	0.00%	+4.77%	-0.27%	-2.10%	-27.53%
IRTC iRhythm Technologies	0.00%	+5.32%	+27.84%	+18.52%	+139.31%
LQDA Liquidia Technologies	0.00%	+3.43%	+42.99%	+74.85%	+168.94%
STVN Stevanato Group	0.00%	-0.13%	-18.76%	+1.26%	+17.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GKOS Glaukos	4.7266 of 5 stars	4.4	4.0	0.0	4.4	2.8	1.7	0.6
IRTC iRhythm Technologies	1.3222 of 5 stars	2.5	1.0	0.0	0.0	3.1	0.8	0.6
LQDA Liquidia Technologies	3.5326 of 5 stars	3.5	3.0	0.0	0.0	3.0	4.2	0.6
STVN Stevanato Group	2.1495 of 5 stars	0.0	4.0	1.7	0.0	2.3	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GKOS Glaukos	2.79	Moderate Buy	$127.42	35.25% Upside
IRTC iRhythm Technologies	3.00	Buy	$162.64	-3.83% Downside
LQDA Liquidia Technologies	3.00	Buy	$32.11	19.64% Upside
STVN Stevanato Group	2.83	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest LQDA, STVN, IRTC, and GKOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$167.00 ➝ $183.00
8/20/2025	IRTC iRhythm Technologies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$200.00
8/15/2025	GKOS Glaukos	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	LQDA Liquidia Technologies	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
8/13/2025	LQDA Liquidia Technologies	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$33.00 ➝ $41.00
8/13/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $31.00
8/12/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/1/2025	IRTC iRhythm Technologies	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/1/2025	IRTC iRhythm Technologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$145.00 ➝ $190.00
8/1/2025	IRTC iRhythm Technologies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$139.00 ➝ $170.00
8/1/2025	IRTC iRhythm Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $180.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GKOS Glaukos	$383.48M	14.09	N/A	N/A	$13.34 per share	7.06
IRTC iRhythm Technologies	$591.84M	9.18	N/A	N/A	$3.23 per share	52.36
LQDA Liquidia Technologies	$14M	165.05	N/A	N/A	$0.18 per share	149.11
STVN Stevanato Group	€1.15B	5.96	€0.75 per share	29.97	€5.24 per share	4.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GKOS Glaukos	-$146.37M	-$1.65	N/A	N/A	N/A	-21.43%	-8.59%	-6.61%	11/3/2025 (Estimated)
IRTC iRhythm Technologies	-$113.29M	-$2.93	N/A	N/A	N/A	-14.06%	-90.03%	-8.52%	10/29/2025 (Estimated)
LQDA Liquidia Technologies	-$130.39M	-$1.70	N/A	N/A	N/A	-732.17%	-232.96%	-60.81%	N/A
STVN Stevanato Group	€127.45M	€0.54	41.70	38.83	2.13	11.73%	10.34%	6.21%	N/A

Latest LQDA, STVN, IRTC, and GKOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LQDA Liquidia Technologies	-$0.43	-$0.49	-$0.06	-$0.49	$3.90 million	$8.84 million
7/31/2025	Q2 2025	IRTC iRhythm Technologies	-$0.53	-$0.32	+$0.21	-$0.44	$173.94 million	$186.69 million
7/30/2025	Q2 2025	GKOS Glaukos	-$0.26	-$0.24	+$0.02	-$0.34	$115.49 million	$124.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	N/A	N/A	N/A	N/A	1 Years

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GKOS Glaukos	0.09	5.51	4.69
IRTC iRhythm Technologies	6.25	5.02	4.88
LQDA Liquidia Technologies	9.84	2.49	2.41
STVN Stevanato Group	0.25	1.79	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
LQDA Liquidia Technologies	64.54%
STVN Stevanato Group	N/A

Insider Ownership

Company	Insider Ownership
GKOS Glaukos	5.80%
IRTC iRhythm Technologies	1.10%
LQDA Liquidia Technologies	26.50%
STVN Stevanato Group	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GKOS Glaukos	780	57.35 million	54.02 million	Optionable
IRTC iRhythm Technologies	2,000	32.13 million	31.78 million	Optionable
LQDA Liquidia Technologies	50	86.09 million	63.28 million	Optionable
STVN Stevanato Group	5,521	302.84 million	300.72 million	Optionable

LQDA, STVN, IRTC, and GKOS Headlines

Recent News About These Companies

Stevanato Group S.p.A. (NYSE:STVN) Receives Average Recommendation of "Moderate Buy" from Analysts

August 21 at 2:22 AM | marketbeat.com

Stevanato Group S.p.A. $STVN Shares Acquired by LPL Financial LLC

August 20, 2025 | marketbeat.com

Stevanato Group S.p.A. (NYSE:STVN) Receives Average Rating of "Moderate Buy" from Analysts

August 20, 2025 | americanbankingnews.com

Deutsche Bank AG Has $19.19 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 15, 2025 | marketbeat.com

USNA vs. STVN: Which Stock Is the Better Value Option?

August 12, 2025 | zacks.com

93,709 Shares in Stevanato Group S.p.A. (NYSE:STVN) Bought by Zions Bancorporation National Association UT

August 10, 2025 | marketbeat.com

Brokers Set Expectations for Stevanato Group Q3 Earnings

August 9, 2025 | marketbeat.com

Blair William & Co. IL Purchases 137,625 Shares of Stevanato Group S.p.A. (NYSE:STVN)

August 9, 2025 | marketbeat.com

William Blair Predicts Stronger Earnings for Stevanato Group

August 8, 2025 | marketbeat.com

Jackson Square Partners LLC Has $23.65 Million Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 8, 2025 | marketbeat.com

CenterBook Partners LP Raises Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

August 8, 2025 | marketbeat.com

Mutual of America Capital Management LLC Grows Holdings in Stevanato Group S.p.A. (NYSE:STVN)

August 7, 2025 | marketbeat.com

Stevanato Group (NYSE:STVN) Stock Price Down 8.6% - Here's What Happened

August 6, 2025 | marketbeat.com

Stevanato Group (NYSE:STVN) Issues FY 2025 Earnings Guidance

August 6, 2025 | marketbeat.com

Stevanato Group S.p.A.: Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

August 6, 2025 | finanznachrichten.de

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

August 6, 2025 | finance.yahoo.com

Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates

August 5, 2025 | zacks.com

Stevanato Group Reports Revenue of â‚¬280.0 Million for the Second Quarter of 2025

August 5, 2025 | businesswire.com

Stevanato Group S.p.A.'s (NYSE:STVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

August 4, 2025 | finance.yahoo.com

Thornburg Investment Management Inc. Sells 12,214 Shares of Stevanato Group S.p.A. (NYSE:STVN)

July 30, 2025 | marketbeat.com

Premier Fund Managers Ltd Acquires Shares of 34,951 Stevanato Group S.p.A. (NYSE:STVN)

July 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LQDA, STVN, IRTC, and GKOS Company Descriptions

Glaukos NYSE:GKOS

$94.21 +4.42 (+4.92%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$94.17 -0.04 (-0.04%)

As of 08/22/2025 06:43 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$169.12 +2.44 (+1.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$169.13 +0.01 (+0.01%)

As of 08/22/2025 07:57 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Liquidia Technologies NASDAQ:LQDA

$26.84 -0.46 (-1.68%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$26.92 +0.09 (+0.32%)

As of 08/22/2025 07:52 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Stevanato Group NYSE:STVN

€22.52 -0.33 (-1.44%)

As of 08/22/2025 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time